Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxervate versus vehicle in severe Sjogren's dry eye disease
2021-003346-21Phase 3Completed
- Sponsor
- Dompé
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of cenegermin in Sjögren's syndrome and dry eye syndrome (DED) (2 arms), sponsored by Dompé. Primary endpoint: Schirmer I responder rate at Week 4. Started Sep 2021; status: completed.
02
Drugs
cenegermin
03
Conditions
Sjögren's syndromedry eye syndrome (DED)
Beyond the preview
Go deeper on 2021-003346-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003346-21.